Additionally, the data identified potential roles of BCL6 and TP53 pathways in ME/CFS etiology and emphasized the importance of investigating adverse reactions to medication and supplements and drug interactions in ME/CFS severity and progression. The gene discussed is BCL6; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.